About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Psychiatry, Mental Health and Addictions Research Group at the Vall d'Hebron Research Institute is a multidisciplinary team that over the past 13 years has focused its scientific activity on the research (both nationally and internationally) of clinical, therapeutic and etiopathogenic aspects of:
At international level, it participates and/or coordinates several European projects of great repercussion in the area of mental health. At national level, it is part of the CIBERSAM (Centre for Biomedical Research in Mental Health Network) together with other leading groups, conducting research of excellence.
PMID: 37857131 Journal: PSYCHIATRY RESEARCH Year: 2023 Reference: Psychiatry Res. 2023 Oct 11;329:115540. doi: 10.1016/j.psychres.2023.115540. Impact factor: Publication type: Paper in international publication Authors: Abdalla, Ebtesam; Abdelrazek, Ibrahim M; Alaaeldin, Khoshoua; Antoni Ramos-Quiroga, Josep; Arlt, Annabelle; Artem, Borovikov; Caro, Pilar; Daigre-Blanco, Constanza; Devriendt, Koen; Ebstein, Frederic et al. DOI: 10.1016/j.psychres.2023.115540
PMID: 37034728 Journal: Year: 2023 Reference: medRxiv. 2023 Sep 18:2023.03.27.23287713. doi: 10.1101/2023.03.27.23287713. Preprint. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Abraira, L; Ballve, A; Batzler, Anthony; Bianchi, Sevim B; Biernacka, Joanna M; Campos, D; Coombes, Brandon J; Cox, Nancy J; Davis, Lea K; Ehinmowo, Michael et al. DOI: 10.1101/2023.03.27.23287713
PMID: 37937232 Journal: Frontiers in Psychiatry Year: 2023 Reference: Front Psychiatry. 2023 Oct 23;14:1293663. doi: 10.3389/fpsyt.2023.1293663. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Anton-Galindo, Ester; Cabana-Dominguez, Judit; Cormand, Bru; Corominas, Roser; Fernandez-Castillo, Noelia; Koulenti, Despoina; Rello, Jordi; Torrico, Barbara; Vandana, Kalwaje Eswhara et al. DOI: 10.3389/fpsyt.2023.1293663
PMID: 37940409 Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Year: 2023 Reference: J Neurol Neurosurg Psychiatry. 2023 Nov 8:jnnp-2023-332251. doi: 10.1136/jnnp-2023-332251. Impact factor: Publication type: Paper in international publication Authors: Abdelhak, Ahmed; Alvarez-Lafuente, Roberto; Anton-Galindo, Ester; Bachhuber, Franziska; Benkert, Pascal; Berek, Klaus; Blanco, Yolanda; Cabana-Dominguez, Judit; Castillo-Trivino, Tamara; Comabella, Manuel et al. DOI: 10.1136/jnnp-2023-332251
PMID: 33657553 Journal: EUROPEAN ADDICTION RESEARCH Year: 2021 Reference: Eur Addict Res. 2021;27(5):326-331. doi: 10.1159/000511770. Epub 2021 Mar 3. Impact factor: 3.015 Publication type: Letter or abstract Authors: Laconi, Stephanie, Palma-Alvarez, Raul Felipe, Stover, Heino, Padberg, Christina, Jamin, Daniela, Meroueh, Fadi, Chappuy, Mathieu, Roncero, Carlos, Rolland, Benjamin et al. DOI: 10.1159/000511770
PMID: 33648696 Journal: Revista colombiana de psiquiatria Year: 2021 Reference: Rev Colomb Psiquiatr. 2021 Jan-Mar;50(1):43-46. doi: 10.1016/j.rcp.2019.10.005. Epub 2020 Jan 21. Impact factor: 0 Publication type: Letter or abstract Authors: Grau-Lopez, Lara, Ros-Cucurull, Elena, Abad, Alfonso Carlos, Dualde, Julia, Robles-Martinez, Maria, Roncero, Carlos, Palma-Alvarez, Raul Felipe et al. DOI: 10.1016/j.rcp.2019.10.005
PMID: 33649707 Journal: Research in Autism Spectrum Disorders Year: 2021 Reference: Res Autism Spectr Disord. 2021 May;83:101757. doi: 10.1016/j.rasd.2021.101757. Epub 2021 Feb 25. Impact factor: 2.881 Publication type: Paper in international publication Authors: Ramos Quiroga, Josep Antoni, Soriano Dia, Albert, Lugo Marin, Jorge, Gisbert Gustemps, Laura, Setien Ramos, Imanol, Espanol Martin, Gemma, Ibanez Jimenez, Pol, Forner Puntonet, Mireia, Arteaga-Henriquez, Gara, Duque Yemail, Juan David et al. DOI: 10.1016/j.rasd.2021.101757
PMID: 33627840 Journal: MOLECULAR PSYCHIATRY Year: 2021 Reference: Mol Psychiatry. 2021 Jul;26(7):3663. doi: 10.1038/s41380-021-01049-6. Impact factor: 15.992 Publication type: Letter or abstract Authors: Franke, Barbara, Faraone, Stephen V, Casas, Miguel, Ramos-Quiroga, Josep Antoni, Ribases, Marta, Neale, Benjamin M, Borglum, Anders D, Vink, Jacqueline M, Stringer, Sven, Soler Artigas, Maria et al. DOI: 10.1038/s41380-021-01049-6
Irritability in ADHD and BDP is an understudied symptom that has a major impact on patients' quality of life and may even increase the risk of suicide.
These results reinforce the need for more individualized attention to address educational needs from an early stage.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
